The estimated Net Worth of David L. Lucchino is at least $11.6 Millón dollars as of 18 August 2023. Mr. Lucchino owns over 5,922 units of Frequency Therapeutics Inc stock worth over $190,123 and over the last 5 years he sold FREQ stock worth over $4,033,045. In addition, he makes $7,364,600 as President, Chief Executive Officer, Co-Founder y Director at Frequency Therapeutics Inc.
David has made over 52 trades of the Frequency Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,922 units of FREQ stock worth $3,257 on 18 August 2023.
The largest trade he's ever made was exercising 113,690 units of Frequency Therapeutics Inc stock on 21 June 2021 worth over $69,351. On average, David trades about 11,415 units every 22 days since 2019. As of 18 August 2023 he still owns at least 633,744 units of Frequency Therapeutics Inc stock.
You can see the complete history of Mr. Lucchino stock trades at the bottom of the page.
David L. Lucchino serves as President, Chief Executive Officer, Co-Founder, Director of the Company. From December 2014 until June 2016, Mr. Lucchino served as the President and Chief Executive Officer of Entrega Bio, a PureTech Health-founded biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of the company’s lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. Mr. Lucchino is the chairman of the board of directors of MassBio, a non-profit organization that represents and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Commonwealth’s Economic Planning Council. Mr. Lucchino also serves as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of Advisors of Life Science Cares. Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology’s, or MIT’s, Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University.
As the President, Chief Executive Officer, Co-Founder y Director of Frequency Therapeutics Inc, the total compensation of David Lucchino at Frequency Therapeutics Inc is $7,364,600. There are no executives at Frequency Therapeutics Inc getting paid more.
David Lucchino is 51, he's been the President, Chief Executive Officer, Co-Founder y Director of Frequency Therapeutics Inc since 2014. There are 10 older and 6 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
David's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer y Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include: